Japanese firm adds ex-Norvartis and Alnylam in-house counsel

Former in-house counsel at major pharma companies brings expertise in IP strategy, regulatory compliance, and business development across pharma and biotech.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Careers

Former head of litigation at Nokia returns to Bird & Bird

18 August 2026 The new partner counts pharmaceuticals and life sciences among his specialisms and previously worked in-house at Sandoz.

Careers

Former USPTO acting director takes the helm at C4IP

17 August 2026 The IP advocacy group has turned to former USPTO acting director Coke Morgan Stewart as it enters what it calls a “new chapter”.

Careers

Holland & Hart adds high-stakes patent litigation team from Ashurst Perkins Coie

13 August 2026 Less than a month after the merger between Ashurst and Perkins Coie, the new team brings expertise in high-stakes patent matters—including medtech and biotech—in the US.

More features

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

10x Genomics dealt major blow in sequencing fight

SK Biopharmaceuticals settles epilepsy generic dispute

Vanda revives challenge over braille-free label on generic sleep disorder drug

Abbott fends off Chinese rival’s patent challenge at UPC

Former head of litigation at Nokia returns to Bird & Bird

Former USPTO acting director takes the helm at C4IP

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

Japanese firm adds ex-Norvartis and Alnylam in-house counsel

More on this story

Editor's picks

Editor's picks

More features